期刊文献+

纾萎方治疗慢性萎缩性胃炎临床观察 被引量:3

Clinical observation of "Shuwei Decoction" in treating chronic atrophic gastritis
下载PDF
导出
摘要 目的观察纾萎方治疗慢性萎缩性胃炎(CAG)的临床疗效。方法将86例CAG患者随机分为治疗组(44例)和对照组(42例),分别给予纾萎方和胃复春治疗,疗程6个月。观察两组临床症状和病理组织的变化情况。结果治疗组的病理组织和中医证候总有效率分别为72.73%和93.18%,均高于对照组的47.62%和38.10%(P<0.05);治疗后两组胃黏膜萎缩情况及胃黏膜腺体IM、ATP改变均有明显改善(P<0.05,P<0.01),且治疗组的改善优于对照组(P<0.05)。结论纾萎方治疗慢性萎缩性胃炎可明显改善临床症状,减轻其胃黏膜IM及ATP变化。 Objective To observe the clinical efficacy of "Shuwei Decoction" in the treatment of chronic atrophic gastritis(CAG).Methods Eighty-six CAG cases were randomly divided into two groups: treatment group in which 44 cases were treated by "Shuwei Decoction" and control group in which 42 cases were treated by "Wei Fu Chun",with a course of six months.The clinical efficacy and pathological changes were observed after treatment.Results The total effective rates for clinical efficacy and pathology were 72.73% and 93.18% in the treatment group,higher than 47.62% and 38.10% in the control group(P0.05);after treatment,the gastric mucosa atrophy,intestinal metaplasia and atypical hyperplasia were relieved in both groups(P0.05,P0.01),with more significant relief in the treatment group than in the control group(P0.05).Conclusion "Shuwei Decoction" can improve the clinical symptoms and relieve intestinal metaplasia and atypical hyperplasia in chronic atrophic gastritis.
出处 《上海中医药杂志》 2011年第5期51-52,62,共3页 Shanghai Journal of Traditional Chinese Medicine
基金 上海市浦东新区社会发展局卫生科技发展专项基金资助项目(PW2009E-7) 上海市浦东新区中医继承型人才培养资助项目(PWZ2008-20-j07)
关键词 慢性萎缩性胃炎 纾萎方 中医药疗法 Chronic atrophic gastritis "Shuwei Decoction" Chinese medicine
  • 相关文献

参考文献5

二级参考文献37

  • 1李哲夫,王德昭,乐竹琴.胃泌素与胃癌[J].国外医学(消化系疾病分册),1993,13(2):69-72. 被引量:11
  • 2Rugge M,Correa P,Dixon MF,Fiocca R,Hattori T,Lechago J,Leandro G,Price AB,Sipponen P,Solcia E,Watanabe H,Genta RM.Gastric mucosal atrophy:interobserver consistency using new criteria for classification and grading.Aliment Pharmacol Ther,2002,16:1249~1259. 被引量:1
  • 3Rugge M,Genta RM.Staging and grading of chronic gastritis.Hum Pathol,2005,36:228~233. 被引量:1
  • 4Price AB.The Sydney System:histological division.J Gastroenterol Hepatol,1991,6:209~222. 被引量:1
  • 5Dixon MF,Genta RM,Yardley JH,Correa P.Classification and grading of gastritis.The updated Sydney System.International Workshop on the Histopathology of Gastritis,Houston 1994.Am J Surg Pathol,1996,20:1161~1181. 被引量:1
  • 6Testino G.Gastric preneoplastic changes.Recenti Prog Med,2004,95:239~244. 被引量:1
  • 7Ferlay J,Bray F,Pisani P,Parkin DM.GLOBOCAN 2000:Cancer Incidence,Mortality and Prevalence Worldwide.Version 1.0.IARC Cancer Base No.5.Lyon:IARC Press,2001. 被引量:1
  • 8Sipponen P,Kekki M,Haapakoski J,Ihamaki T,Siurala M.Gastric cancer risk in chronic atrophic gastritis:statistical calculations of cross-sectional data.Int J Cancer,1985,35:173~177. 被引量:1
  • 9Koga M,Miyakawa K,Ikeda S.Annual Report of Gastroenterological Mass Survey in Japan,2002.Tokyo:Japanese Society of Gastroenterology Mass Survey.2004. 被引量:1
  • 10Sipponen P,Ranta P,Helske T,Kaariainen I,Maki T,Linnala A,Suovaniemi O,Alanko A,Harkonen M.Serum levels of amidated gastrin-17 and pepsinogen Ⅰ in atrophic gastritis:an observational case-control study.Scand J Gastroenterol,2002,37:785~791. 被引量:1

共引文献131

同被引文献12

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部